management skin reactions cancer patients receiving epidermal growth factor receptor targeted therapies pubmed ncbi abstract epidermal growth factor receptor egfr inhibitors treatment solid tumours increasing tolerability profile egfr-inhibitors monoclonal antibody cetuximab tyrosine kinase inhibitor erlotinib characterised unique group skin reactions dominated acneiform eruption xerosis eczema hair nails possibility skin toxicity correlates anti-tumour activity offers potential titrate dosing case-by-case basis skin effects constitute significant obstacle treatment compliance consistent multi-disciplinary management strategies patients receive recommended dosages targeted therapies eruption responds acne therapies xerosis controlled standard emollients present overview treatment options skin reactions today evaluate ways treatment egfr-inhibitor-related skin reactions improved future evidence-based studies needed determine manage effects 
